Dr. Aleksander Sekulic on Vismodegib in Patients with Basal Cell Nevus Syndrome

Aleksandar Sekulic, MD, PhD, Assistant Professor of Dermatology, Mayo Clinic, Scottsdale, AZ, explains the positive data that came from a recent study of the hedgehog pathway inhibitor vismodegib. Vismodegib decreased the size of existing basal cell carcinomas and reduced the number of new basal cell carcinomas in patients with basal cell nevus syndrome (Gorlin syndrome).

For more information visit: http://targetedhc.com/